EUVIMEDEUVIMED entdecken
Crossref

AIEgen‐Based Biomimetic Nanoplatform for Targeted Synergistic Sonodynamic Therapy and Macrophage Reprogramming of Hyperhomocysteinemic Atherosclerosis

Yue Jia, Bin Li, Qin Gu, Yunlong Zhang, Shuo Sang, Fei Ma, Changting He, Yongli Wang, Yanqiu Wu, Duo Jiang, Xueting Liu, Han Duan und 11 weitere

Small · 31.07.2026

DOI: 10.1002/smll.74733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 31.07.2026. Verfasst von Yue Jia und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Projects (Research on Prevention and Treatment of Cancer, Cardiovascular and Cerebrovasc…, National Natural Science Foundation of China, Key Research and Development Program of Ningxia Hui Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The instability and subsequent rupture of atherosclerotic plaques are driven primarily by the progressive enlargement of the lipid‐rich necrotic cores coupled with local macrophage dysfunction, which readily trigger life‐threatening acute cardiovascular and cerebrovascular events. Homocysteine serves as an independent risk factor for atherosclerosis. Here, we developed a synergistic nanotherapeutic strategy for hyperhomocysteinemic atherosclerosis (HHcy‐AS) by simultaneously targeting foam cells and diseased macrophages. Specifically, an aggregation‐induced emission (AIE) sonosensitizer TTPY‐COOH was encapsulated into OPN antibody‐modified polymer nanoparticles to form TP‐Ab cores, which were then co‐loaded with dexamethasone into ROS‐responsive platelet membrane‐liposome hybrid vesicles, yielding the final nanodrug TP‐Ab/Dex@PL. Following intravenous injection, this nanoplatform utilizes platelet membranes to precisely target atherosclerotic plaques, where it rapidly disassembles within the high ROS environments. The released TP‐Ab cores selectively deliver TTPY‐COOH to foam cells via specific antibody recognition, where subsequent ultrasound‐triggered sonodynamic therapy induces cellular apoptosis. Meanwhile, locally released dexamethasone exhibits a robust anti‐inflammatory effect and reprograms M1 macrophages into the M2 phenotype, enhancing their efferocytosis for apoptotic foam cells. In an HHcy‐AS mouse model, TP‐Ab/Dex@PL treatment significantly reduced plaque burden and improved plaque stability. This multifunctional nanoplatform integrates sonodynamic therapy, anti‐inflammatory effects, and macrophage reprogramming, offering potential for the precise clinical treatment of atherosclerosis.

Schlagwörter

Stichwörter der Autor:innen

aggregation‐induced emissionhyperhomocysteinemic atherosclerosismacrophage reprogrammingprecision therapysonodynamic therapy

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China.
  • NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, Ningxia, China.
  • School of Inspection, Ningxia Medical University, Yinchuan, Ningxia, China.
  • Department of Critical Care Medicine & Department of Emergency, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Institute For Engineering Medicine, Kunming Medical University, Kunming, Yunnan, China.
  • Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Dong Wang, Shengchao Ma, Yuhui Liao, Yideng Jiang

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Projects (Research on Prevention and Treatment of Cancer, Cardiovascular and Cerebrovasc…
  • National Natural Science Foundation of China
  • Key Research and Development Program of Ningxia Hui Autonomous Region
  • Natural Science Foundation of Ningxia-Outstanding Youth Program
  • Open Competition Mechanism to Select the Best Candidates for Key Research Projects of Ningxia Medical University

Zitieren

APA

Jia, Y., Li, B., Gu, Q., Zhang, Y., Sang, S., Ma, F., He, C., Wang, Y., Wu, Y., Jiang, D., Liu, X., Duan, H., Fu, X., Wei, Z., Liao, W., Liu, Z., Wang, W., Wang, J., Hao, Y., …, & Jiang, Y. (2026). AIEgen‐Based Biomimetic Nanoplatform for Targeted Synergistic Sonodynamic Therapy and Macrophage Reprogramming of Hyperhomocysteinemic Atherosclerosis. Small. https://doi.org/10.1002/smll.74733

Vancouver

Jia Y, Li B, Gu Q, Zhang Y, Sang S, Ma F, et al. AIEgen‐Based Biomimetic Nanoplatform for Targeted Synergistic Sonodynamic Therapy and Macrophage Reprogramming of Hyperhomocysteinemic Atherosclerosis. Small. 2026. doi:10.1002/smll.74733

BibTeX
@article{Jia2026,
  author = {Jia, Yue and Li, Bin and Gu, Qin and Zhang, Yunlong and Sang, Shuo and Ma, Fei and He, Changting and Wang, Yongli and Wu, Yanqiu and Jiang, Duo and Liu, Xueting and Duan, Han and Fu, Xinting and Wei, Zihui and Liao, Weihao and Liu, Zihuan and Wang, Weihan and Wang, Jiamei and Hao, Yinju and Wang, Dong and Ma, Shengchao and Liao, Yuhui and Jiang, Yideng},
  title = {AIEgen‐Based Biomimetic Nanoplatform for Targeted Synergistic Sonodynamic Therapy and Macrophage Reprogramming of Hyperhomocysteinemic Atherosclerosis},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.74733}
}
Kostenlos starten →